AngioSoma (OTCMKTS:SOAN – Get Free Report) and Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Insider & Institutional Ownership
0.0% of AngioSoma shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk and Volatility
AngioSoma has a beta of -0.46, suggesting that its stock price is 146% less volatile than the S&P 500. Comparatively, Decoy Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AngioSoma | 0 | 0 | 0 | 0 | 0.00 |
| Decoy Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Decoy Therapeutics has a consensus price target of $30.00, suggesting a potential upside of 466.04%. Given Decoy Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Decoy Therapeutics is more favorable than AngioSoma.
Profitability
This table compares AngioSoma and Decoy Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AngioSoma | N/A | N/A | -1,245.34% |
| Decoy Therapeutics | N/A | -395.42% | -193.30% |
Earnings and Valuation
This table compares AngioSoma and Decoy Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AngioSoma | N/A | N/A | -$540,000.00 | N/A | N/A |
| Decoy Therapeutics | N/A | N/A | -$12.52 million | ($106.90) | -0.05 |
Summary
Decoy Therapeutics beats AngioSoma on 7 of the 9 factors compared between the two stocks.
About AngioSoma
AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.
About Decoy Therapeutics
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Receive News & Ratings for AngioSoma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioSoma and related companies with MarketBeat.com's FREE daily email newsletter.
